Close

Roth Capital Resumes AcelRx Pharmaceuticals (ACRX) at Buy

July 9, 2015 4:51 PM EDT Send to a Friend
Roth Capital resumes coverage on AcelRx Pharmaceuticals (NASDAQ: ACRX) with a Buy rating and a price target of $7.50.Analyst Michael ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login